

**BAXTER INTERNATIONAL INC.**  
**Net Sales**  
**Periods Ending June 30, 2011 and 2010**  
**(unaudited)**  
**(\$ in millions)**

	Q2 2011	Q2 2010	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2011	YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
United States	\$687	\$636	8%	8%	\$1,371	\$1,246	10%	10%
International	866	722	20%	11%	1,590	1,474	8%	5%
<b>Total BioScience</b>	<b>\$1,553</b>	<b>\$1,358</b>	<b>14%</b>	<b>10%</b>	<b>\$2,961</b>	<b>\$2,720</b>	<b>9%</b>	<b>7%</b>
<b>Medical Products <sup>1</sup></b>								
United States <sup>2</sup>	\$722	\$710	2%	2%	\$1,452	\$1,384	5%	5%
International	1,251	1,114	12%	4%	2,389	2,206	8%	4%
<b>Total Medical Products - Adjusted <sup>2</sup></b>	<b>\$1,973</b>	<b>\$1,824</b>	<b>8%</b>	<b>3%</b>	<b>\$3,841</b>	<b>\$3,590</b>	<b>7%</b>	<b>4%</b>
COLLEAGUE infusion pump charge <sup>2</sup>						(213)		
<b>Total Medical Products - GAAP <sup>2</sup></b>	<b>\$1,973</b>	<b>\$1,824</b>	<b>8%</b>	<b>3%</b>	<b>\$3,841</b>	<b>\$3,377</b>	<b>14%</b>	<b>11%</b>
<b>Transfusion Therapies <sup>3</sup></b>								
United States	\$9	\$9	0%	0%	\$17	\$18	(6%)	(6%)
International	1	3	(67%)	(67%)	1	6	(83%)	(83%)
<b>Total Transfusion Therapies</b>	<b>\$10</b>	<b>\$12</b>	<b>(17%)</b>	<b>(17%)</b>	<b>\$18</b>	<b>\$24</b>	<b>(25%)</b>	<b>(25%)</b>
<b>Baxter International Inc.</b>								
United States <sup>2</sup>	\$1,418	\$1,355	5%	5%	\$2,840	\$2,648	7%	7%
International	2,118	1,839	15%	7%	3,980	3,686	8%	4%
<b>Total Baxter - Adjusted <sup>2</sup></b>	<b>\$3,536</b>	<b>\$3,194</b>	<b>11%</b>	<b>6%</b>	<b>\$6,820</b>	<b>\$6,334</b>	<b>8%</b>	<b>5%</b>
COLLEAGUE infusion pump charge <sup>2</sup>						(213)		
<b>Total Baxter - GAAP <sup>2</sup></b>	<b>\$3,536</b>	<b>\$3,194</b>	<b>11%</b>	<b>6%</b>	<b>\$6,820</b>	<b>\$6,121</b>	<b>11%</b>	<b>9%</b>

<sup>1</sup> Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

<sup>2</sup> GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures.

<sup>3</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture.